Abstract
STING1 is an immune adaptor protein which promotes innate immune defense mechanisms against pathogens. Its role in modulating inflammation links STING1 to various pathologic conditions, positioning it as a key target for therapeutic interventions aimed at regulating immune responses. To advance our understanding of STING1-associated diseases, it is essential to make high-performing antibodies readily accessible to the scientific community. This study aims to improve reliability of STING1 research as we have characterized sixteen STING1 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.
Funder
Genome Canada
Michael J. Fox Foundation for Parkinson’s Disease Research
Genome Quebec
Mitacs
Ontario Genomics